Highest-materiality recent filing
Twist Bioscience files prospectus supplement to register resale of shares to Invenra
Registers resale of shares issuable under Feb 11, 2026 Stock Purchase Agreement with Invenra Inc.
Anthropic selects Twist Bioscience as evaluator for AI-designed protein campaign across 15 targets
Anthropic chose Twist as independent evaluator for multi-arm protein design campaign against 15 targets.
Twist Bioscience prices upsized $300M public offering of common stock at $96/share
Offering of 3,125,000 shares at $96.00 per share; underwriters' option for 468,750 additional shares exercised in full.
Twist Bioscience Q3 FY2026 revenue $118.4M (+23% YoY); raises FY guidance to $456-457M
Record revenue of $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth.
Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M
Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).
Twist Bioscience to issue up to 632,328 shares for Invenra license and equity stake
Total consideration: up to 632,328 TWST shares plus $5M cash.
Keith Crandell, Jan Johannessen, and Trynka Shineman Blake elected as Class II directors with over 40M votes for each.
Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M
Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.
Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance
Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.
Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.
Twist Bioscience appoints Trynka Shineman Blake to Board of Directors
Trynka Shineman Blake elected to Twist board and appointed to Audit Committee, effective August 5, 2025.
Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M
Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.
Twist reports record Q2 revenue $92.8M; spins out DNA data storage as Atlas with $155M investment
Record Q2 revenue $92.8M (+23% YoY); gross margin 49.6% vs 41.0%.
Twist Bioscience shareholders approve 100M share increase, equity plan amendment
Shareholders approved increase in authorized common stock by 100,000,000 shares (Proposal Five).
Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M
Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.
FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.
Twist Bioscience enters month-to-month consulting agreement with James Thorburn at $25K/mo
James Thorburn's previous employment agreement as Strategic Advisor expired; new consulting deal effective October 8, 2024.
Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M
Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.
Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance
Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).
Twist Bioscience stockholders elect Leproust and Chess as directors at annual meeting
Emily M. Leproust re-elected with 33,957,330 votes for, 12,194,829 withheld; Robert Chess with 27,503,789 for, 18,648,370 withheld.
Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.
Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024
Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.
FY2023 revenue $245.1M, up 20% from $203.6M; orders $264M, up 17% from $226.4M.
Twist Bioscience reports $12.7M restructuring costs, exceeding prior $9-11M estimate
Cumulative pre-tax restructuring costs of $12.7M recognized through June 30, 2023.
Twist Bioscience reports Q3 FY2023 revenue of $63.7M (up 14% YoY); CFO to transition to new role
Revenue $63.7M, up 14% YoY from $56.1M; net loss $57.4M ($1.01/share) vs $60.5M prior year.
Twist Bioscience appoints Robert Werner as Chief Accounting Officer
Robert Werner appointed Chief Accounting Officer effective May 22, 2023; James Thorburn continues as CFO.
Twist Bioscience Q2 revenue record $60.2M (+25% YoY); cuts 270 jobs (~25% workforce)
Revenue $60.2M, up 25% YoY; orders $64.2M, up 17% YoY.
Kevin Yankton resigns as CAO effective May 19, 2023 to pursue other interests; no disagreement with company.
Twist Bio annual meeting elects directors, approves say-on-pay, ratifies auditor
Keith Crandell and Jan Johannessen elected as Class II directors with 33.9M and 32.2M votes for, respectively.
Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows
Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.
Twist Bioscience amends bylaws to add proxy access for 3% long-term stockholders
Proxy access provision allows stockholders/groups of up to 20 owning ≥3% for ≥3 years to nominate up to 2 or 20% of directors.
Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M
FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.
Twist Bioscience refutes Scorpion Capital short-seller report as misleading; Q4 results Nov 18
Twist calls Scorpion Capital report 'highly misleading' with many distortions and inaccuracies.
Twist Bioscience promotes Patrick Finn to President and COO
Patrick Finn, formerly Chief Commercial Officer, appointed President and COO effective October 25, 2022.
Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M
Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).
Twist Bioscience Q2 revenue $48.1M (+54% YoY), orders $55.0M (+32% YoY)
Record revenue $48.1M, up 54% YoY from $31.2M.
Twist Bioscience COO Patrick Weiss steps down; internal promotions announced
Patrick Weiss resigns as COO effective April 21, 2022, for personal reasons; will stay as strategic advisor.
Twist Bioscience dismisses PwC, appoints EY as independent auditor
PwC dismissed as auditor on March 3, 2022; its FY2020 and FY2021 audit reports were unqualified.
Twist Bioscience launches ~$287.5M common stock offering at $55.00 per share
Issued 5,227,272 shares (including full exercise of underwriter option) at $55.00 per share.
Twist Bioscience shareholders elect four Class I directors at 2022 annual meeting
Nelson Chan re-elected with 20.5M for, 22.2M withheld; Xiaoying Mai with 33.5M for, 9.1M withheld.
Twist Bioscience Q1 FY2022: revenue $42M (+49% YoY), orders up 48%, raises FY guidance
Revenue of $42.0M (up 49% from $28.2M YoY); orders of $49.6M (up 48% from $33.6M).
Twist Bioscience completes acquisition of Abveris (AbX Biologics)
Acquisition closed December 1, 2021, under merger agreement dated November 19, 2021.
Twist Bioscience appoints Dr. Melissa Starovasnik to Compensation Committee
Dr. Melissa Starovasnik was appointed to the Compensation Committee of the Board on November 17, 2021.
Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M
FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.
Twist Bioscience to acquire Abveris for up to $190M in stock and cash
Total consideration up to $190M: $150M at close (Twist stock + up to $10M cash) plus up to $40M stock tied to 2022 revenue target.
Twist Bioscience appoints drug discovery leader Melissa Starovasnik to board
Dr. Starovasnik appointed to board effective Aug 5, 2021; will receive $40k cash retainer (pro rata) and $340k in equity vesting over 3 years.
Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance
Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).
On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.
As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.
On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.
appointed Robert F. Werner as the Company’s chief accounting officer and principal accounting officer, effective May 22, 2023.
Mr. Thorburn will serve as the Company’s principal accounting officer until a successor to Mr. Yankton is appointed, in addition to his current role as the Company’s Chief Financial Officer.
On March 23, 2023, Kevin Yankton, Chief Accounting Officer of Twist Bioscience Corporation (the “Company”), provided notice of his resignation from the Company effective May 19, 2023, to pursue other interests.
On October 25, 2022, the Board of Directors of Twist Bioscience Corporation (the “Company”) appointed Patrick Finn as President and Chief Operating Officer of the Company, effective immediately.
On April 20, 2022, Patrick Weiss notified Twist Bioscience Corporation (the “Company”) that he is stepping down as the Company’s Chief Operating Officer effective April 21, 2022.
On August 5, 2021, the Board of Directors (the “ Board ”) of Twist Bioscience Corporation (the “ Company ”) elected Dr. Melissa Starovasnik to the Board, effective immediately.
On August 5, 2021, Board appointed Kevin Yankton, the Company’s Chief Accounting Officer, as principal accounting officer, effective August 5, 2021.
James Thorburn, the Company’s Chief Financial Officer, previously served as principal accounting officer and will continue to serve as Chief Financial Officer and principal financial officer.
Max materiality 0.90 · Median 0.70 · Most common event earnings